Feed COGT
CO

Cogent Biosciences, Inc. COGT · NASDAQ

$30.01 +1.66% (+$0.49)

Market cap
$5.21B
Enterprise value
$5.27B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-50.1%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.31
Free float
89.8%

About the company

Cogent Biosciences, Inc. (COGT) is an American biotechnology company focused on the development of innovative therapeutics for patients with oncological and genetic diseases. With a primary emphasis on targeted therapy and gene therapy, Cogent Biosciences aims to provide effective and personalized treatments. Their research and development efforts are centered on identifying new therapeutic targets and discovering innovative approaches to treatment. The shares of Cogent Biosciences, Inc. (COGT) may be suitable for investors seeking opportunities in the field of biotechnology and innovative therapeutics with potential in oncology and genetic diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Andrew R. Robbins

Employees

258

Headquarters

Waltham

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.